Compare Smith & Nephew plc (SNN) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Thomson Reuters Corp — how do they compare? Smith & Nephew plc trades at $30.05 (market cap $12.50B), while Thomson Reuters Corp trades at $104.52 (market cap $45.08B). The key difference: Thomson Reuters Corp is far larger — about 3.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| SNN | TRI | |
|---|---|---|
Market Cap | $12.50B | $45.08B |
Sector | Health | Industrials |
52-Week High | $38.70 | $178.77 |
52-Week Low | $28.73 | $76.55 |
Enterprise Value | $15.53B | $47.69B |
Dividend Yield | 2.64% | 2.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $30.11, up 1.41% in the last session. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 revenue growth of 1.6% but cut its full-year outlook to 4% from 6% due to weakness in U.S. Orthopaedics and Advanced Wound Bioactives (MarketBeat, 2026-08-09). Recent product launches include the LYNX COBLATION Wand and CORI XT robotics platform, supporting innovation in medical technology.
The outlook is mixed: strong profitability margins and recent earnings beats offer support, but lowered guidance and bearish technicals pose near-term headwinds. Risks include execution challenges in key markets, while analyst consensus leans Hold, reflecting cautious optimism amid growth uncertainties.
Thomson Reuters (TRI) trades at $101.83, up 1.68% today, near the consensus price target of $102.33. The stock shows strong technical momentum with bullish moving averages and support at $99. Fundamentally, TRI delivered Q2 2026 earnings beat ($0.99 vs. $0.96 expected) with 8% organic revenue growth, while maintaining robust profitability margins (21.22% net income margin). Recent news highlights AI-driven product momentum and raised full-year revenue guidance.
Outlook remains positive with analyst consensus favoring Buy (51.85%) and 29.8% upside potential to high target of $124. Key risks include execution on AI transition and competitive pressures in legal/tax software markets. The company's recurring revenue model (82% of total) and dividend payments provide stability amid growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
